MedWatch

Novo Nordisk Pharmatech closes distribution agreement for Russia and CIS countries

Novo Nordisk Pharmatech has entered an extensive partnership agreement for Russia and CIS countries with Czech company IMCoPharma.

Photo: Novo Nordisk Pharmatech/PR

The ingredient-producing subsidiary of Novo Nordisk, Novo Nordisk Pharmatech, has entered an agreement with IMCoPharma for the distribution of the company's Quats (synthetic molecules) to the healthcare industry in Russia and countries in the Commonwealth of Independent States (CIS), according to Pharmaceutical Business review.

"I am very happy for our collaboration with Novo Nordisk Pharmatech, which started already at the end of 2020 in several CIS countries. We are proud to be a partner of an experienced European company with exceptional healthcare products and represent their product portfolio among our customers across Eastern Europe and Middle Asian countries," says IMCoPharma Commercial Director Lukas Adamec in a press release.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs